Medicines access advocates have welcomed the licensing deal signed this month by the US National Institutes of Health with two global organizations for 11 innovative COVID-19 products, saying that the political significance of the move “cannot be ignored.”
NGOs Praise C-TAP COVID-19 Deals But Say Much More Needs To Be Done
The WHO Is Negotiating Additional Agreements
With efforts continuing to maximize access to medical countermeasures against the pandemic threat, a webinar organized by NGOs looked at progress with and the shortcomings of the WHO’s C-TAP initiative, recent moves by the WHO on access provisions in funding agreements, and plans for a global C-TAP database.
More from International
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
• By
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
• By
The Australian Therapeutic Goods Administration proposed a narrower indication that Eisai rejected.
More from Geography
• By
The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.
• By
Eli Lilly’ will request a re-examination after the European Medicines Agency declined to recommend its Alzheimer’s disease drug Kisunla for EU approval.
• By
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.